<- Go Home
2seventy bio, Inc.
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company’s products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Market Cap
$266.1M
Volume
610.6K
Cash and Equivalents
$92.4M
EBITDA
-$52.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$13.2M
Profit Margin
27.37%
52 Week High
$5.30
52 Week Low
$2.29
Dividend
N/A
Price / Book Value
1.23
Price / Earnings
-63.66
Price / Tangible Book Value
1.26
Enterprise Value
$332.5M
Enterprise Value / EBITDA
-7.20
Operating Income
-$59.4M
Return on Equity
1.94%
Return on Assets
-7.49
Cash and Short Term Investments
$170.4M
Debt
$239.8M
Equity
$214.0M
Revenue
$48.4M
Unlevered FCF
-$40.4M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium